Plus Therapeutics (NASDAQ: PSTV) presented positive results from the FORESEE study of its CNSide platform for diagnosing and managing leptomeningeal metastases (LM) at the 2024 SNO/ASCO CNS Metastases Conference. The trial, involving 39 patients with breast or non-small cell lung cancer, met its primary and secondary endpoints. Key findings include:
CNSide influenced treatment decisions in over 90% of cases
80% sensitivity in detecting tumor cells compared to 29% for CSF cytology
Identified actionable mutations, influencing 24% of therapeutic selections
High specificity with no false positives
These results suggest CNSide's potential for earlier LM diagnosis and improved patient management.